ACTRN12610000317099尚未招募未知
Pilot trial invovling students at the University of Otago Wellington to determine the level of calcium phosphate mineral deposisted in dental plaque in vivo using a novel plaque mineralising toothpaste as a procedure to protect against dental caries.
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 30 Years（—）
- 性别
- All
入选标准
- •Radiation Therapy and Medical Students at the University of Otago Wellington
排除标准
- •Requirement to treat for periodontal disease or other immediate dental treatment needed.
- •History of rheumatic heart disease/fever
研究者
相似试验
已完成
不适用
A pilot of a school-based program to foster effective bystander responses to racism and racial bullying among teachers and students in Australian schools.ACTRN12617000880347Australian National University1,200
进行中（未招募）
1 期
The influence of the medication Willfact on the blood loss of patient during the use of a heart-lung machineVon Willebrand Disease (VWD)MedDRA version: 19.1Level: PTClassification code 10069495Term: Acquired Von Willebrand's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-000789-53-ATMedizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
已完成
不适用
A pilot physical activity intervention for middle-aged Arab-Australian womePhysical inactivityPublic Health - Health promotion/educationACTRN12618001392257Western Sydney University22
进行中（未招募）
不适用
A single center, open, pilot study to evaluate the pharmacokinetic profile of a new galenic formulation of an Ambroxol-Hydrochloride (Ambroxol-HCl) spray: Ambroxol CYATHUS” 50 mg/mL Oral Spray, administered in a single dose of 30 mg Ambroxol-HCl to healthy male volunteersMedDRA version: 8.1Level: LLTClassification code 10006440Term: Bronchial obstructionEUCTR2006-005291-41-ATCYATHUS Exquirere PharmaforschungsGmbH
进行中（未招募）
1 期
Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the new SARS-CoV-2 coronavirus (COVID-19)COVID-19 infection is being spread around the world with more than 400.000 cases. The spred of the disease is being a world health problem.EUCTR2020-001194-69-ESFélix Gutiérrez Rodero200